#United States #Sapience Therapeutics #Tarrytown #ST316 #Familial Adenomatous Polyposis

Sapience Therapeutics Celebrates Key Regulatory Milestone

Sapience Therapeutics, Inc., a pioneering biotechnology company focused on developing innovative peptide therapeutics, has recently achieved an important milestone in its drug development journey. The U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for ST316, designed specifically for the treatment of Familial Adenomatous Polyposis (FAP). This rare inherited disorder predisposes individuals to the development of numerous precancerous polyps in the colon and rectum, significantly increasing their risk of colorectal cancer.

Understanding Familial Adenomatous Polyposis (FAP)

FAP is primarily caused by mutations in the APC gene. Those affected by this condition can develop hundreds or even thousands of adenomatous polyps beginning in their teenage years, leading to nearly universal progression to colorectal cancer if left untreated. The current management approaches heavily rely on proactive surveillance and surgical interventions, which underscores an urgent need for effective medical treatments that can alleviate disease symptoms and minimize the need for surgical procedures.

The Significance of ST316

ST316 stands out for its unique mechanism of action, selectively targeting and inhibiting the oncogenic activity of β-catenin while minimizing side effects that usually accompany broader Wnt pathway inhibitors. The potential for safety and tolerability is critical for long-term treatments in FAP, where stringent safety profiles are requisite.

Barry Kappel, CEO of Sapience Therapeutics, expressed his excitement regarding this regulatory achievement, stating, "ST316's distinct therapeutic approach enables a focused inhibition of β-catenin activity. With the promising safety and efficacy profile that was indicated in our Phase 1 clinical studies, we are optimistic about its potential impact on patients suffering from FAP."

Clinical Activity and Future Trials

ST316 has already shown preliminary efficacy in a Phase 2 expansion study for patients with second-line metastatic colorectal cancer (2L mCRC). Initial results highlighted a confirmed objective response rate (ORR) of 47%, in which patients responded positively to the combination therapy of ST316 with standard treatment options. The progression-free survival and disease control rates reflect significantly improved outcomes compared to historical data of current treatment modalities in the same patient population.

With the current IND acceptance, Sapience is also positioning ST316 to be further assessed in various β-catenin-driven conditions beyond FAP, showcasing its versatile therapeutic potential.

The Road Ahead

As the only known medical therapy in development for FAP, ST316's acceptance for IND represents a beacon of hope for individuals living with this severe genetic condition. Currently, there are no FDA-approved targeted therapies for FAP, further emphasizing the significance of this development.

Research indicates that FAP affects approximately 1 in 5,000 to 10,000 individuals in the United States, according to the National Organization for Rare Disorders (NORD). The prospect of a robust therapeutic solution could transform the standard of care and enhance the quality of life for many.

Sapience's commitment to advancing the understanding and treatment of cancer through their lead programs, such as ST316 and lucicebtide, continues to pave the way for breakthroughs in therapeutic interventions against singularly challenging diseases, heralding a new era in precision medicine.

For more information about Sapience Therapeutics and their research initiatives, please visit their official website and follow their latest updates on professional social media channels.